Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, ATRA is expected to report 3Q20 loss of $ 1.09 per share.
For the full year, analysts anticipate loss of $ 4.53 per share bottom line.
Stock Performance
On Friday, shares of Atara Biotherapeutics, Inc. has traded high as $ 14.10 and has cracked $ 13.39 on the downward trend, reaching $ 13.45 with volume of 823.40 thousand shares.
According to the previous trading day, closing price of $ 13.45, representing a 207.08 % increase from the 52 week low of $ 4.52 and a 28.31 % decrease over the 52 week high of $ 19.36.
The company has a market capital of $ 1.01 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th September 2020, maintained by Canaccord Genuity at Buy rating, with $ 78.00 target price.
Conference Call
Atara Biotherapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.atarabio.com
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis.
